About Afon Technology
Afon Technology is a medical device business on a mission to develop Glucowear™, a completely non-invasive, continuous blood glucose monitor. Glucowear™ will empower people with diabetes with the information they need to better manage their condition on a daily basis.
- Non-Invasive Glucose Monitoring
- Continuous Glucose Monitor
- Accurate Blood Glucose Readings
Poised to revolutionise blood glucose monitoring
Afon Technology Ltd is poised to revolutionise blood glucose monitoring, offering Glucowear as a continuous, pain-free and real-time solution for individuals with diabetes and those at risk. Glucowear addresses the critical challenges with the current monitoring landscape, empowering people with diabetes to better manage their condition.
Afon is making significant progress as we enter clinical trials ahead of our anticipated launch in 2025. This is an exciting phase that brings us closer to delivering an innovative solution for the diabetes market.
Stay tuned for more news as it happens, and thank you for your continued support and interest in our journey.
Glucowear will reinvent diabetes management from a medicalised “patient” centric positioning to one of freedom from the disease; be proactive and empowered and manage their condition with a fun, fashionable, lifestyle accessory.
Our History
Afon Technology has come a long way since the concept of its life changing technology was discovered in by Dr Sabih Chaudhry (Founder & CEO).
Dr Chaudhry worked with the Royal Liverpool Hospital in 2013 to conduct the first trials on the technology and was also awarded the Bionow Award for Healthcare Project of the Year in 2014.
Since then, Dr Chaudhry has secured further private investment as well as being awarded grant funding and has built up a team of skilled and dedicated staff who have developed the technology for manufacture and are preparing for commercialisation.
The team at Afon Technology consists of world-renowned experts as well as people who are passionate about improving the lives of others.
Afon Technology have carried out several independent clinical trials with their Glucowear™ device which includes an ongoing NHS trial.
In December 2022, Afon Technology were awarded a €2.5m grant from the European Innovation Council. Afon were one of only six UK based winners to be awarded this prestigious prize funding from amongst thousands of applicants across Europe. This grant is designed to help individual start-ups and small companies to develop and scale up game changing innovations.
